Log In
BCIQ
Print this Print this
 

VAL-0411 (formerly 4s3-002)

  Manage Alerts
Collapse Summary General Information
Company Valerion Therapeutics LLC
DescriptionFusion protein of the delivery antibody 3E10 linked to muscleblind (MBNL1)
Molecular Target Muscleblind (MBNL1)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMyotonic dystrophy type 1 (DM1)
Indication DetailsTreat myotonic dystrophy type 1 (DM1)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today